Novo Nordisk to acquire Emisphere Technologies for $1.8 billion

Novo Nordisk agreed to acquire Emisphere Technologies for $1.35 billion in cash plus $450 million for related royalty obligations, totaling $1.8 billion. The deal gives Novo Nordisk full ownership of the Eligen drug delivery platform.

“The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been successfully used under a license agreement to develop the first oral biologic, Rybelsus.”roi-nj.com

• 1 source
• roi-nj.comNovo Nordisk buying Roseland’s Emisphere and its Eligen drug-delivery platform in $1.8B deal | ROI-NJEric StraussNov 6, 2020

Summarized from public sources; check the original articles before acting on it.